The FDA Accepts Insmed's Supplemental New Drug Application For Review Of Arikayce (Amikacin Liposome Inhalation Suspension) For Mycobacterium Avium Complex Lung Disease As Part Of Combination Antibacterial Drug Regimen, With Target Action Date Of January 28, 2027

뉴스 본문을 불러오고 있어요.

The FDA Accepts Insmed's Supplemental New Drug Application For Review Of Arikayce (Amikacin Liposome Inhalation Suspension) For Mycobacterium Avium Complex Lung Disease As Part Of Combination Antibacterial Drug Regimen, With Target Action Date Of January 28, 2027 | 웨이프 WAPE

The FDA Accepts Insmed's Supplemental New Drug Application For Review Of Arikayce (Amikacin Liposome Inhalation Suspension) For Mycobacterium Avium Complex Lung Disease As Part Of Combination Antibacterial Drug Regimen, With Target Action Date Of January 28, 2027

기사 요약

관련 종목

댓글 —